PharmaFocus: Supportive Care in Oncology

  • ID: 4459367
  • Report
  • 199 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Acacia Pharma
  • Cellerant Therapeutics
  • Helsinn
  • Myelo Therapeutics GmbH
  • Roche
  • Soligenix Inc.
  • MORE
PharmaFocus: Supportive Care in Oncology

Summary

Supportive care in oncology is a broad term that is composed of indications that are either a symptom of a patient’s cancer or a side effect of cancer treatment. This report focuses on six prominent cancer supportive care indications: chemotherapy-induced nausea and vomiting (CINV), cancer cachexia, oral mucositis, bone metastases, chemotherapy-induced neutropenia (CIN), and chemotherapy-induced anemia (CIA).

There is a consensus among KOLs across the 7MM that supportive oncology had not been given much priority by physicians and institutions in the past. However, there is also a consensus that this situation has been improving in recent years, with increasing recognition of the importance of supportive care.

A growing library of evidence indicates that supportive care: increases likelihood of completing treatment, without the need for dose reductions or treatment pauses; can reduce costs for healthcare institutions; and can improve quality of life for patients-all of which will become increasingly important as patients continue to live longer and cancer progresses to become more like a chronic disease. Despite the trends in oncology towards targeted therapies, KOLs agree that chemotherapy will remain the backbone of cancer treatment for the next five to 10 years. Thus, as the incidence of cancer rises over the next 10 years, so will the cases of chemotherapy-related conditions, in addition to a rise in general oncology-related conditions.

Scope
  • Highlight KOL views on the past, present, and future trends in supportive care in oncology in their countries
  • Provide cancer and cancer supportive care epidemiological insight
  • Provide an overview of the market landscape and available therapies
  • Provide an overview of all late-stage (Phase II and III) candidates and evaluate the prominent pipeline agents that are closest to market entry
  • Identify the unmet needs and opportunities in each indication
  • Highlight R&D strategies used by developers in this field, alongside clinical trial design considerations and challenges
  • Provide detailed key opinion leader insight throughout each indication and aspect of this report.
Reasons to buy

The report will enable you to:
  • Develop business strategies by understanding the trends shaping and driving the global supportive care in oncology market
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global supportive care market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acacia Pharma
  • Cellerant Therapeutics
  • Helsinn
  • Myelo Therapeutics GmbH
  • Roche
  • Soligenix Inc.
  • MORE
1 Table of Contents

2 Executive Summary
2.1 Traditionally Overlooked Field, but Recognition of Supportive Oncology is Growing Across the 7MM, and will Continue to do so in the Next Five to Ten Years.
2.2 Marketed Landscape Varies Significantly - Blockbuster Drugs in CIN, CIA, and Bone Metastases, but Nothing Available for Cancer Cachexia
2.3 CIN and Oral Mucositis Possess the Largest Late Stage (Phase II and III) Pipelines
2.4 Unmet Needs Remain in Each Indication, Primarily in Cancer Cachexia and Oral Mucositis, Given the Lack of Effective Therapies
2.5 R&D and Clinical Trial Design in Supportive Oncology Presents Unique Challenges
2.6 What Do Physicians Think?

3 Introduction
3.1 Objectives
3.2 Related Reports

4 Supportive Care in Oncology Global Landscape: KOL Views
4.1 Overview
4.2 US Supportive Care Landscape
4.3 UK Supportive Care Landscape
4.4 Germany Supportive Care Landscape
4.5 Spain Supportive Care Landscape
4.6 Japan Supportive Care Landscape
4.7 Guidelines Followed by KOLs

5 Epidemiology
5.1 Cancer Background, Global and Historic Trends
5.2 Methodology and Sources
5.3 Epidemiology for Supportive Care in Oncology (2016-2026)
5.4 Discussion, Limitations and Strengths of Analysis

6 Marketed Products
6.1 Chemotherapy-Induced Nausea and Vomiting
6.2 Cancer Cachexia
6.3 Oral Mucositis
6.4 Bone Metastases
6.5 Chemotherapy-Induced Neutropenia
6.6 Chemotherapy Induced Anemia

7 Pipeline Assessment
7.1 Chemotherapy-Induced Nausea and Vomiting
7.2 Cancer Cachexia
7.3 Oral Mucositis
7.4 Bone Metastases
7.5 Chemotherapy-Induced Neutropenia
7.6 Chemotherapy-Induced Anemia

8 Unmet Needs and Opportunities
8.1 Chemotherapy-Induced Nausea and Vomiting
8.2 Cancer Cachexia
8.3 Oral Mucositis
8.4 Bone Metastases
8.5 Chemotherapy-Induced Neutropenia
8.6 Chemotherapy-Induced Anemia

9 R&D Strategies and Clinical Trial Design
9.1 Overview of Clinical Development in Supportive Oncology
9.2 Chemotherapy-Induced Nausea and Vomiting
9.3 Cancer Cachexia
9.4 Oral Mucositis
9.5 Bone Metastasis
9.6 Chemotherapy-Induced Neutropenia
9.7 Chemotherapy-Induced Anemia

10 Appendix
10.1 Bibliography
10.2 Abbreviations
10.3 Primary Research - KOLs Interviewed for This Report
10.4 About the Authors
10.5 About
10.6 Contact Us
10.7 Disclaimer

List of Tables
Table 1: 7MM, Diagnosed Incident Cases of All Cancer, Men and Women, Ages =20 Years
Table 2: CINV Marketed Products Overview
Table 3: Types of CINV
Table 4: Product Profile - Emend
Table 5: Product Profile - Emend for Injection / IVemend
Table 6: Product Profile - Varubi and Varubi IV
Table 7: Product Profile - Aloxi
Table 8: Product Profile - Sustol
Table 9: Product Profile - Akynzeo
Table 10: Product Profile - Kepivance
Table 11: Bone Metastases Marketed Products Overview
Table 12: Product Profile - Xgeva
Table 13: Product Profile - Xofigo
Table 14: Product Profile - Zometa
Table 15: Product Profile - Aredia
Table 16: CIN Marketed Products Overview
Table 17: Product Profile - Neupogen
Table 18: Filgrastim Biosimilars
Table 19: Product Profile - Granix
Table 20: Product Profile - Granocyte
Table 21: Product Profile - Neulasta
Table 22: Product Profile - Lonquex
Table 23: Product Profile - Leukine
Table 24: CIA Marketed Products Overview
Table 25: National Cancer Institute Anemia Scale
Table 26: Product Profile - Procrit/Eprex/Epogen
Table 27: Epoetin Alfa Biosimilars
Table 28: Product Profile - NeoRecormon
Table 29: Product Profile - Eporatio/Biopoin
Table 30: Product Profile - Aranesp
Table 31: CINV Phase II and III Pipeline
Table 32: APD403 (Amisulpride) - Acacia Pharma, SWOT Analysis, 2017
Table 33: Cinvanti (Aprepitant/HTX-019) - Heron Therapeutics, SWOT Analysis, 2017
Table 34: Cancer Cachexia Phase II and III Pipeline
Table 35: Adlumiz (Anamorelin) - Helsinn, SWOT Analysis, 2017
Table 36: Xilonix (MABp1) - XBiotech, SWOT Analysis, 2017
Table 37: Oral Mucositis Phase II and III Pipeline
Table 38: Phase III Clinical Development Programs for SGX942 (Dusquetide) in Oral Mucositis
Table 39: SGX942 (Dusquetide) - Soligenix, SWOT Analysis, 2017
Table 40: Validive (Clonidine Lauriad) - Onxeo / Monopar Therapeutics, SWOT Analysis, 2017
Table 41: Bone Metastases Phase II and III Pipeline
Table 42: Phase III Clinical Development Programs for Tanezumab - Pfizer and Eli Lilly in Bone Metastases
Table 43: Tanezumab - Pfizer and Eli Lilly, SWOT Analysis, 2017
Table 44: CIN Phase II and III Pipeline
Table 45: Phase III Clinical Development Program for Rolontis (Eflapegrastim/SPI-2012 - Spectrum Pharmaceuticals and Hanmi Pharmaceuticals) in CIN
Table 46: Rolontis (Eflapegrastim/SPI-2012) - Spectrum Pharmaceuticals and Hanmi Pharmaceuticals, SWOT Analysis, 2017
Table 47: Phase II/III Clinical Development Programs for Plinabulin (NPI-2358) - BeyondSpring Pharmaceuticals in CIN
Table 48: Plinabulin (NPI-2358) - BeyondSpring Pharmaceuticals, SWOT Analysis, 2017
Table 49: CIA Phase II and III Pipeline
Table 50: SPP-003 (5-Aminolevulinic Acid Hydrochloride and Sodium Ferrous Citrate) - SBI Pharmaceuticals, SWOT Analysis, 2017
Table 51: Oral Mucositis Pipeline Agents: Methods of Administration
Table 52: Definitions of the Most Common CINV Trial Endpoints
Table 53: Oral Mucositis Late-Stage Pipeline Agents: FDA Fast Track Designations
Table 54: Primary Endpoints Used in Trials for Oral Mucositis Pipeline Agents
Table 55: Examples of Primary and Secondary Endpoints that Can Be Studied in CIN Trials
Table 56: Common Outcomes of Interest in Anemia Clinical Trials

List of Figures
Figure 1: 7MM, Age-Standardized Diagnosed Incidence of All Cancer, Men, Ages =18 Years, 2016-2026
Figure 2: 7MM, Age-Standardized Diagnosed Incidence of All Cancer, Women, Ages =18 Years, 2016-2026
Figure 3: 7MM, Sources Used to Forecast Diagnosed Incident Cases of All Cancer
Figure 4: 7MM, Sources Used to Forecast Five-Year Diagnosed Prevalent Cases of All Cancer
Figure 5: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Prostate Cancer
Figure 6: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Breast Cancer
Figure 7: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Lung Cancer
Figure 8: 7MM, Sources Used to Forecast Chemotherapy-Induced Conditions
Figure 9: 7MM, Sources Used to Forecast Bone Metastasis in Prostate, Breast, and Lung Cancer
Figure 10: 7MM, Diagnosed Incident Cases of All Cancer Receiving Chemotherapy Treatment, Men and Women, Ages =18 Years
Figure 11: 7MM, Diagnosed Incident Cases of All Cancer With Chemotherapy-Induced Conditions, Men and Women, Ages =18 Years
Figure 12: 7MM, Diagnosed Incident Cases of Prostate Cancer, Men, Ages =35 Years
Figure 13: 7MM, Diagnosed Incident Cases of Prostate Cancer That Have Developed or Will Develop Bone Metastasis, Men, Ages =35 Years
Figure 14: 7MM, Diagnosed Incident Cases of Breast Cancer, Women, Ages =20 Years
Figure 15: 7MM, Diagnosed Incident Cases of Breast Cancer That Have Developed or Will Develop Bone Metastasis, Women, Ages =20 Years
Figure 16: 7MM, Diagnosed Incident Cases of Lung Cancer, Men and Women, Ages =20 Years
Figure 17: 7MM, Diagnosed Incident Cases of Lung Cancer That Have Developed or Will Develop Bone Metastasis, Men and Women, Ages =20 Years
Figure 18: 7MM, Five-Year Diagnosed Prevalent Cases of All Cancer, Men and Women, All Ages
Figure 19: Unmet Needs and Opportunities in CINV, 2017
Figure 20: Unmet Needs and Opportunities in Cancer Cachexia, 2017
Figure 21: Unmet Needs and Opportunities in Oral Mucositis 2017
Figure 22: Unmet Needs and Opportunities in Bone Metastases, 2017
Figure 23: Unmet Needs and Opportunities in CIN, 2017
Figure 24: Unmet Needs and Opportunities in CIA 2017
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Acacia Pharma
  • Aeterna Zentaris
  • Amgen
  • Aphios Corporation
  • Bayer
  • BeyondSpring Pharmaceuticals
  • Biocon
  • Cellerant Therapeutics
  • Coherus Biosciences
  • Eli Lilly
  • Enzychem Lifesciences Corp
  • Galera Therapeutics
  • Gedeon Richter
  • Generon (Shanghai) Corp Ltd
  • Hanmi Pharmaceuticals
  • Helsinn
  • Heron Therapeutics
  • Innovation Pharmaceuticals
  • Insys Therapeutics
  • Johnson & Johnson
  • Merck & Co.
  • Monopar Therapeutics
  • Myelo Therapeutics GmbH
  • Mylan
  • Novartis
  • Onxeo
  • Paradigm BioPharma
  • Pfizer
  • Roche
  • R-Pharm US LLC
  • Sandoz
  • Sanofi-Aventis
  • SBI Pharmaceuticals
  • Sobi
  • Soligenix Inc.
  • Spectrum Pharmaceuticals
  • Spherium Biomed
  • Taiho Pharmaceutical
  • Tanvex biopharma Inc
  • Tesaro
  • Teva
  • USV Pvt Ltd
  • XBiotech
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll